GEO DataSets

(Submitter supplied) The samples include RNA from scalp biopsies before treatment and at 8 weeks of treatment with Tofacitinib Citrate 5 mg BID in patients with Alopecia Areata. 32% had a SALT score of 50% or higher and 47% had clinically significant response.

Organism:

Homo sapiens

Type:

Expression profiling by high throughput sequencing

Platform:

GPL11154

56 Samples

Download data: TXT

(Submitter supplied) This study was an open-label, clinical trial to investigate tofacitinib 5 mg to 10 mg PO twice daily in the treatment of moderate/severe alopeica areata and to identify if gene expression of the scalp correlates with clinical response. Gene expression profiling was performed on scalp biopsies of alopecia areata patients taken at baseline and up to 24 weeks of treatment of tofacitinib. We applied both naïve and supervised clustering to this dataset in order to assess two features: the overall molecular effect of tofacitinib treatment on patient samples, and the concordant molecular response of the disease. more...

Organism:

Homo sapiens

Type:

Expression profiling by high throughput sequencing

Platform:

GPL16791

18 Samples

Download data: TXT

(Submitter supplied) This goal of these studies were to examine gene expression profiles of skin from patients with alopecia areata undergoing treatment with oral ruxoltinib. Microarray analysis was performed to assess changes in gene expression in affected scalp skin.

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL570

31 Samples

Download data: CEL

(Submitter supplied) To define the molecular response to JAKi treatment, we performed RNA-seq analysis on a series of skin biopsies taken before and after systemic treatment with INCB039110 (JAK1i), CEP-33779 (JAK2i), PF-06651600 (JAK3i), ruxolitinib (JAK1/2i), tofacitinib (pan-JAKi) or vehicle control.

Organism:

Mus musculus

Type:

Expression profiling by high throughput sequencing

Platform:

GPL21103

24 Samples

Download data: XLSX

(Submitter supplied) We present the biopsy sub-study results from the first randomized, placebo-controlled clinical trial in patients with alopecia areata (AA) with ≥50% scalp hair loss and ≤7 years since the last AA episode. In this sub-study, we evaluated the molecular responses to PF-06651600, an oral inhibitor of JAK3 and the tyrosine kinase expressed in hepatocellular carcinoma (TEC) kinase family, and PF-06700841, an oral TYK2/JAK1 inhibitor, versus placebo in nonlesional and lesional scalp biopsies of biopsy samples from patients with AA.

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL570

129 Samples

Download data: CEL

(Submitter supplied) Two patients with alopecia areata were treated with systemic ruxolitinib. Skin biopsies were taken before starting treatment and 12 weeks after starting treatment. We used microarrays to assess changes in gene expression of affected skin before and after starting treatment

Organism:

Homo sapiens

Type:

Expression profiling by array

Dataset:

GDS5275

Platform:

GPL570

7 Samples

Download data: CEL

(Submitter supplied) Flow sorted CD3+CD8+CD44+CXCR3+NKG2D+ lymph node cells from C3H/HeJ mice with alopecia were flow sorted and profiled in relation to CD3+CD8+CD44+CXCR3+NKG2D- lymph node cells from the same host

Organism:

Mus musculus

Type:

Expression profiling by high throughput sequencing

Platform:

GPL13112

6 Samples

Download data: TXT

(Submitter supplied) Our goal was to identify gene expression patterns that correlated with prevention of autoimmune alopecia in C3H/HeJ mice following alopecic graft transplantation skin from 3-5 mice were taken at 5/6 weeks and 12/13 weeks of drug administration following grafting; mice were treated with ruxolitinib (jak12i) by oral gavage, tofacitinib (jak3i) by osmotic pump, antiIL15R-beta antibody by i.p. injection, or control pbs by either ip injection, oral gavage, or osmotic pump. more...

Organism:

Mus musculus

Type:

Expression profiling by array

Platform:

GPL1261

48 Samples

Download data: CEL

(Submitter supplied) Our goal was to identify gene expression patterns that correlated with treatment of established autoimmune alopecia in C3H/HeJ mice following alopecic graft transplantation skin from 3 mice were taken at 6, 12 and, in some cases, 24 weeks of topical drug administration following grafting; mice were treated with ruxolitinib (jak1i), tofacitinib (jak3i), or control pbs

Organism:

Mus musculus

Type:

Expression profiling by array

Dataset:

GDS5273

Platform:

GPL1261

31 Samples

Download data: CEL

(Submitter supplied) Our goal was to develop a transcriptomic description of affected alopecic skin from aged C3H/HeJ mice. Affected skin from 3 mice was compared to skin from similarly aged but unaffected C3H/HeJ mice.

Organism:

Mus musculus

Type:

Expression profiling by array

Dataset:

GDS5274

Platform:

GPL1261

6 Samples

Download data: CEL

(Submitter supplied) Our goal was to develop a transcriptomic description of affected alopecic scalp skin from patients with alopecia areata.

Organism:

Homo sapiens

Type:

Expression profiling by array

Dataset:

GDS5272

Platform:

GPL570

10 Samples

Download data: CEL

Analysis of scalp skin from two alopecia areata (AA) patients treated with oral ruxolitinib for 12 weeks. AA is a T-cell mediated autoimmune disease. Ruxolitinib is a small-molecule inhibitor of the JAK1/2 kinases. Results provide insight into molecular mechanisms underlying the pathogenesis of AA.

Organism:

Homo sapiens

Type:

Expression profiling by array, transformed count, 2 agent, 2 disease state, 5 individual, 2 time sets

Platform:

GPL570

Series:

GSE58573

7 Samples

Download data: CEL

Analysis of alopecic skin from C3H/HeJ animals. The C3H/HeJ strain develops spontaneous alopecia areata (AA) with high similarity to human AA. AA is an autoimmune disease resulting from damage of hair follicle by T cells. Results provide insight into molecular mechanisms underlying AA pathogenesis.

Organism:

Mus musculus

Type:

Expression profiling by array, transformed count, 2 disease state sets

Platform:

GPL1261

Series:

GSE45513

6 Samples

Download data: CEL

Analysis of skin from C3H/HeJ grafted recipients with established alopecia areata (AA) following alopecic graft transplantation that were treated with topical Janus kinase (JAK) inhibitor ruxolitinib or tofacitinib for up to 24 wks. Results provide insight into molecular basis of AA pathogenesis.

Organism:

Mus musculus

Type:

Expression profiling by array, transformed count, 3 agent, 4 time sets

Platform:

GPL1261

Series:

GSE45514

31 Samples

Download data: CEL

Analysis of scalp skin from patients with alopecia areata (AA). AA is a common autoimmune disease resulting from damage of the hair follicle by T cells. Results provide insight into the molecular mechanisms underlying AA pathogenesis.

Organism:

Homo sapiens

Type:

Expression profiling by array, transformed count, 2 disease state sets

Platform:

GPL570

Series:

GSE45512

10 Samples

Download data: CEL

(Submitter supplied) This SuperSeries is composed of the SubSeries listed below.

Organism:

Homo sapiens; Mus musculus

Type:

Expression profiling by high throughput sequencing

Platforms:

GPL18573 GPL19057

44 Samples

Download data

(Submitter supplied) JAK inhibition by means of clinically available pan JAK inhibitors has recently demonstrated great efficacy in both restoring hair growth and resolving inflammation in the skin of patients with Alopecia Areata (AA). These effects are dose dependent and mainly efficacious at ranges close to a questionable risk profile. Given the great responses to JAK inhibition and the current lack of efficacious treatments in AA, it is exciting to explore the possibilities to separate the beneficial and adverse effects in order to provide a successful treatment option for these patients where the medical need is still vastly unmet. more...

Organism:

Mus musculus

Type:

Expression profiling by high throughput sequencing

Platform:

GPL19057

24 Samples

Download data: TXT

(Submitter supplied) JAK inhibition by means of clinically available pan JAK inhibitors has recently demonstrated great efficacy in both restoring hair growth and resolving inflammation in the skin of patients with Alopecia Areata (AA). These effects are dose dependent and mainly efficacious at ranges close to a questionable risk profile. Given the great responses to JAK inhibition and the current lack of efficacious treatments in AA, it is exciting to explore the possibilities to separate the beneficial and adverse effects in order to provide a successful treatment option for these patients where the medical need is still vastly unmet. more...

Organism:

Homo sapiens

Type:

Expression profiling by high throughput sequencing

Platform:

GPL18573

20 Samples

Download data: TXT

(Submitter supplied) Gene expression profiling of scalp skin biopsies from patients with alopecia areata or normal healthy controls Scalp skin punch biopsies were taken from the indicated patients and stored in PAXgene tissue containers for shipping to a central location, where the samples were processed

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL570

122 Samples

Download data: CEL, TXT

(Submitter supplied) Systemic sclerosis (SSc) is an autoimmune, connective tissue disease characterized by vasculopathy and fibrosis of the skin and internal organs. Trends in efficacy outcome measures favored tofacitnib. Baseline gene expression in fibroblast and keratinocyte subpopulations indicates interferon (IFN) activated gene expression.

Organism:

Homo sapiens

Type:

Expression profiling by high throughput sequencing

Platform:

GPL24676

30 Samples

Download data: MTX, TSV